This is the authors' abstract. We don't add key points for this paper.
We previously demonstrated that glucosamine (GlcN) exerts anti-inflammatory effects through the inhibition of nuclear factor-κB (NF-κB) signaling, possibly via O-linked-N-acetylglucosamine (O-GlcNAc) modification. In this study, we examined the effects of GlcN and alloxan (an inhibitor of O-linked-N-acetylglucosamine transferase) on NF-κB signaling molecules in interleukin (IL)-1β-stimulated human synovial MH7A cells. GlcN-induced O-GlcNAc modification of NF-κB and markedly inhibited IL-1β-induced nuclear translocation of the NF-κB, and phosphorylation of p65 subunit. GlcN also suppressed IL-1β-induced phosphorylation and degradation of inhibitor of κB (IκB). Moreover, GlcN promoted O-GlcNAc modification of IκB kinase (IKK) β, which phosphorylates IκBα, and concurrently inhibited its phosphorylation (activation). Notably, the effects of GlcN on NF-κB, IκBα, and IKKβ were reversed by alloxan. Finally, the inhibitory effect of GlcN on IL-8 production was eliminated in IKKβ-knockdown cells. Collectively, these findings indicate that O-GlcNAc modification of IKKβ is a key mediator of GlcN-induced suppression of NF-κB signaling and inflammatory cytokine production.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Someya et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: